Stock ATORX ALLIGATOR BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

News Alligator Bioscience AB

Equities

ATORX

SE0000767188

Delayed Nasdaq Stockholm
Other stock markets
 10:13:41 2024-04-16 am EDT 		5-day change 1st Jan Change
1.048 SEK -1.13% Intraday chart for Alligator Bioscience AB +6.18% +52.10%
Apr. 05 Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board CI
Mar. 26 Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alligator publishes outcome in rights issue
AQ
Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024
AQ
Notice of annual general meeting in Alligator Bioscience AB
AQ
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board
CI
BioStock: Alligator Bioscience on the importance of prolonging life
AQ
BioStock: Alligator to maximise immuno-oncology innovation
AQ
Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal "mAbs"
AQ
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs
CI
Alligator publishes supplementary prospectus
AQ
Alligator Bioscience publishes Annual Report for 2023
AQ
Alligator Bioscience : The subscription period in Alligator Bioscience's rights issue begins today
PU
BioStock: Alligator's CEO on current development and the rights issue
AQ
The subscription period in Alligator Bioscience’s rights issue begins today
AQ
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
AQ
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
AQ
BioStock: Clinical effects observed with Alligator's 4-1BB agonist
AQ
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
AQ
BioStock: Alligator prepares for phase III with CD40 agonist
AQ
BioStock: Alligator's CEO comments on restructuring plan
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATORX Stock
  4. News Alligator Bioscience AB